Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $262.6 million.

  • UNITED THERAPEUTICS's Other Non-Current Assets rose 43.03% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 43.03%. This contributed to the annual value of $222.1 million for FY2024, which is 46.31% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Other Non-Current Assets stood at $262.6 million, which was up 12.56% from $233.3 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Other Non-Current Assets registered a high of $262.6 million during Q3 2025, and its lowest value of $105.8 million during Q2 2022.
  • Its 3-year average for Other Non-Current Assets is $183.1 million, with a median of $169.1 million in 2024.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first crashed by 40.23% in 2022, then surged by 46.31% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Other Non-Current Assets (Quarterly) stood at $108.2 million in 2021, then grew by 5.64% to $114.3 million in 2022, then soared by 32.81% to $151.8 million in 2023, then spiked by 46.31% to $222.1 million in 2024, then skyrocketed by 43.03% to $262.6 million in 2025.
  • Its last three reported values are $262.6 million in Q3 2025, $233.3 million for Q2 2025, and $222.4 million during Q1 2025.